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This 
 
Journal
 
 feature begins with a case vignette highlighting a common clinical problem. 
Evidence supporting various strategies is then presented, followed by a review of formal guidelines, 
when they exist. The article ends with the author’s clinical recommendations.
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A 10-year-old girl with atopic dermatitis reports itching that has recently become re-
lentless, resulting in sleep loss. Her mother has been reluctant to treat the girl with
topical corticosteroids, because she was told that they damage the skin, but she is ex-
hausted and wants relief for her child. How should the problem be managed?
 
Atopic dermatitis (or atopic eczema) is an itchy, inflammatory skin condition with a
predilection for the skin flexures.
 
1
 
 It is characterized by poorly defined erythema with
edema, vesicles, and weeping in the acute stage and skin thickening (lichenification) in
the chronic stage (Fig. 1A and 1B). Although termed atopic, up to 60 percent of chil-
dren with the clinical phenotype do not have demonstrable IgE-mediated sensitivity to
allergens,
 
2
 
 an observation that led the World Allergy Organization to propose a revised
nomenclature.
 
3
 
 Approximately 70 percent of cases of atopic dermatitis start in chil-
dren under five years of age,
 
4
 
 although 10 percent of cases seen in hospital settings
start in adults.
 
5
 
 Asthma develops in approximately 30 percent of children with atopic
dermatitis, and allergic rhinitis in 35 percent.
 
6
 
diagnostic criteria
 
Atopic dermatitis is difficult to define because of its variable morphology and distribu-
tion and its intermittent nature. Several diagnostic criteria have been developed.
 
7
 
 Con-
sensus criteria for the main clinical features of atopic dermatitis
 
8
 
 have led to a short list
of reliable and valid discriminators that are used worldwide
 
9
 
 (Table 1).
Assessing disease severity is problematic when there is no objective marker.
 
10
 
 The
many severity scales used in clinical trials are generally not suitable for rapid assess-
ment in the clinic.
 
11
 
 The presence or absence of sleep disturbance, the number and lo-
cation of involved sites, and the clinical course are the indicators of severity that prob-
ably provide the best basis for making decisions about treatment.
 
12
 
prevalence, cost, and prognosis
 
According to the International Study of Asthma and Allergies in Childhood, the preva-
lence of symptoms of atopic dermatitis in children six or seven years of age during a
one-year period varied from less than 2 percent in Iran and China to approximately 20
percent in Australia, England, and Scandinavia.
 
13
 
 A high prevalence has also been
found in the United States.
 
14
 
 In the United Kingdom, one population survey of 1760 af-
fected children from one to five years of age found that 84 percent of cases were mild,
14 percent were moderate, and 2 percent were severe.
 
15
 
Studies suggest that atopic dermatitis imposes a high economic burden,
 
16
 
 with out-
of-pocket expenses and overall costs that are similar to those for the treatment of asth-
ma.
 
17
 
 Causes of family stress related to caring for children with moderate or severe
the clinical problem
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atopic dermatitis (e.g., sleep deprivation, loss of em-
ployment, time-consuming treatment, and finan-
cial costs) may rival those related to caring for chil-
dren with diabetes mellitus type 1.
 
18
 
Approximately 60 percent of patients with child-
hood atopic dermatitis are free of symptoms in ear-
ly adolescence,
 
19
 
 although up to 50 percent may
have recurrences in adulthood.
 
20
 
 Early-onset dis-
ease, severe early disease, concomitant asthma and
hay fever, and a family history of atopic dermatitis
may predict a more persistent course.
 
4
 
 One recent
cohort study of 1314 German children showed that
the prognosis was related to disease severity and
atopic sensitization, as evidenced by elevated serum
levels of IgE antibodies to food and inhalant aller-
gens at two years of age.
 
21
 
causes
 
Atopic dermatitis is probably a complex disease re-
lying on the interplay of several factors.
 
22
 
 Several
genes have been identified that may explain some
cases.
 
23
 
 Genetics alone, however, cannot explain
the results of studies of migrant populations that
show, for example, that Jamaican children living in
London are twice as likely to have atopic dermatitis
as Jamaican children living in Jamaica; the increased
risk of atopic dermatitis in smaller families and
among higher social classes; and the rising preva-
lence of atopic dermatitis in some countries. These
observations suggest a key role for the environment
in mediating disease expression.
 
24
 
 Whereas aller-
gens such as house-dust mites and foods may be
important in some cases, nonallergic factors such
as rough clothing, 
 
Staphylococcus aureus 
 
infections,
exposure to microbes during infancy, excessive heat,
and exposure to irritants that disrupt the function
of the skin barrier may also be important. Mecha-
nisms for and implications of the possible preven-
tion of atopic dermatitis are reviewed elsewhere.
 
25,26
 
diagnosis
 
Skin biopsy is of little value in the diagnosis of
atopic dermatitis; instead, diagnosis is based on
clinical features
 
7-9
 
 (Table 1). The differential diag-
strategies and evidence
 
Figure 1. Atopic Dermatitis.
 
Panel A shows acute atopic dermatitis with intense 
erythema and vesicles. Panel B shows chronic atopic 
dermatitis with lichenification (skin thickening and en-
hancement of skin markings) and scaling on the front
of the ankle.
A
B
 
* Adapted from Williams et al.
 
9
 
Table 1. Criteria for the Diagnosis of Atopic Dermatitis.
 
*
 
The diagnosis requires evidence of itchy skin (or parental 
report of scratching or rubbing) plus three or 
more of the following:
History of involvement of the skin creases (e.g., 
fronts of elbows, backs of knees, fronts of ankles, 
and areas around the neck or eyes)
History of asthma or hay fever (or history of atopic 
disease in a first-degree relative if the child is un-
der four years of age)
History of generally dry skin in the past year
Onset in a child under two years of age (criterion not 
used if the child is under four years of age)
Visible flexural dermatitis (including dermatitis af-
fecting the cheeks or forehead and outer aspects 
of limbs in children under four years of age)
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nosis depends on age and the country of residence
(Fig. 2 and Table 2). Because of their high negative
predictive value (above 95 percent), negative skin-
prick or radioallergosorbent tests for foods and en-
vironmental allergens may be useful for assessing
the contribution of allergies to disease expression
in children with severe disease.
 
27
 
 Positive tests are
less useful, with positive predictive values of about
40 percent.
 
27
 
 
Concomitant food allergy may be manifested as
urticaria and gastrointestinal symptoms and may
not necessarily exacerbate atopic dermatitis. Dou-
ble-blind, placebo-controlled food challenges are
the standard for diagnosing associated food aller-
gy, but they are time consuming and not available
in many hospitals. 
The clinical utility of patch testing with airborne
allergens is still unclear.
 
28
 
 Patch tests are useful for
excluding a diagnosis of suspected superimposed
allergic contact dermatitis.
 
29
 
treatment
 
Topical Corticosteroids
 
One systematic review identified 83 randomized
controlled trials of the use of topical corticoste-
roids in atopic dermatitis.
 
30
 
 Vehicle-controlled stud-
ies lasting less than one month indicate that approx-
imately 80 percent of people report good, excellent,
or clear responses with topical corticosteroids,
whereas 38 percent of persons in control groups re-
ported such responses. 
Potency of topical corticosteroids is classified
by the potential for vasoconstriction — a surrogate
for clinical efficacy and skin thinning (Table 3). In
general, only preparations that have very weak or
moderate strength are used on the face and geni-
tal area, whereas those that have moderate or po-
tent strength are used on other areas of the body.
 
31
 
Lower-potency corticosteroids may be sufficient on
all areas of the body in younger children. Prepara-
tions are typically used in bursts of three to seven
days in order to achieve control. There is little dif-
ference in outcome between short-term use of po-
tent preparations or longer use of weaker prepara-
tions in children with mild-to-moderate disease.
 
32
 
Lichenified atopic dermatitis requires more potent
preparations for longer periods. 
Long-term studies of moderate-to-potent prep-
arations in children are scarce. One study of 231
children with stabilized atopic dermatitis randomly
assigned to receive twice-weekly 0.05 percent flutic-
asone propionate (plus emollients) or vehicle alone
plus emollients for 16 weeks showed that patients
in the control group were more likely, by a factor of
8, to have a relapse (95 percent confidence interval,
4.3 to 15.2).
 
33
 
 A four-month trial of persons 12 to
64 years of age with moderate-to-severe disease
showed that the application of fluticasone to pre-
viously active and new sites of atopic dermatitis for
two consecutive days each week reduced flares sig-
nificantly, as compared with a group receiving an
emollient only.
 
34
 
 
Reduced efficacy of topical corticosteroids may
be related to disease severity rather than to glucocor-
ticoid resistance.
 
35
 
 There is little evidence that the
application of topical corticosteroids twice a day is
more effective than once-daily applications,
 
36
 
 and
more frequent use may cause more local side effects.
A main concern with the use of topical cortico-
steroids is irreversible skin thinning. Although thin-
ning is possible, the concern on the part of patients
(and parents) is often well out of proportion to the
true risk.
 
37
 
 Although inappropriate use of potent
preparations can cause skin thinning, four 16-week
randomized trials did not show any clinically sig-
nificant skin thinning,
 
32-34,38
 
 and a 1-year study
showed no significant effect on collagen synthe-
sis.
 
39
 
 A one-year study of unrestricted continual use
of a potent corticosteroid on the limbs and trunk,
a weak preparation on the face, or both showed that
striae developed in 3 of 330 adults with moderate-
to-severe atopic dermatitis.
 
40
 
 Similar studies in chil-
dren are lacking. Other possible side effects of cor-
 
Figure 2. Discoid (Nummular) Eczema in an Infant.
 
This pattern of eczema is frequently associated with atopic dermatitis and is 
often confused with ringworm infection.
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ticosteroids include facial telangiectasia and glau-
coma from periocular use (rarely reported in adults).
Secondary adrenal suppression and the sup-
pression of growth resulting from systemic absorp-
tion of topical corticosteroids are also concerns,
although clinically relevant adrenal suppression
is very rare.
 
41
 
 One study involving children with
atopic dermatitis did not find any relationship be-
tween height velocity and the use of mild-potency
as compared with moderate-potency topical cor-
ticosteroids.
 
42
 
 Another study showed biochemi-
cal evidence of suppression of the hypothalamic–
pituitary–adrenal axis only in children with atopic
dermatitis who used potent or very potent topical
corticosteroids and in those who had received glu-
cocorticoids from other routes, and not in those who
had used topical corticosteroids of mild or mod-
erate strength for a median of 6.9 years.
 
35
 
Emollients
 
There is no evidence that emollients improve atopic
dermatitis directly. However, emollients are wide-
ly used because they improve the appearance and
symptoms of the dry skin (xerosis) associated with
this condition.
 
30,31,43
 
 One study has shown that
emollients may reduce the need for topical corti-
costeroids by approximately 50 percent,
 
44
 
 and an-
other study found that emollients enhanced the re-
sponse to treatment with topical corticosteroids.
 
45
 
There is little basis for suggesting the use of one
emollient over another, and the preference of the
patient is probably the most important factor.
 
31
 
Topical Calcineurin Inhibitors
 
Topical tacrolimus and pimecrolimus have both
been shown to be effective in vehicle-controlled
studies. For 1 percent pimecrolimus, the rate ratio
 
Table 2. Differential Diagnosis of Atopic Dermatitis.
Diagnosis Description
 
Seborrheic dermatitis of infancy Red, shiny, relatively well-demarcated eruptions typically involving the diaper area 
are present in infants four months of age or younger. The lower abdomen and 
armpits may also be involved, and scalp scaling (cradle cap) may be present. 
The infant appears comfortable. The condition clears within a few months.
Adult-type seborrheic dermatitis Poorly defined erythema due to overgrowth of or sensitivity to malassezia yeasts is 
present in seborrheic areas (i.e., sides of nose, eyebrows, external ear canal, 
scalp, front of chest, axillae, and groin creases).
Discoid (nummular) eczema Circular “cracked” areas of erythema 1 to 5 cm in diameter are present initially on 
the limbs, often with secondary infection (Fig. 2). In children, discoid eczema is 
most commonly associated with atopic dermatitis and is often confused with 
tinea (ringworm). In adults, it may be associated with excessive skin dryness 
and secondary infection with 
 
Staphylococcus aureus
 
.
Irritant contact dermatitis Cumulative damage to the skin barrier from irritants such as soaps and detergents 
is present. The clinical appearance can be identical to that of atopic dermatitis, 
but location at sites of maximal exposure (e.g., fingers) may be helpful in mak-
ing the diagnosis. Some degree of irritant contact dermatitis is common in per-
sons with atopic dermatitis (e.g., in babies, around the mouth, owing to saliva 
and wet food, and in the diaper area, owing to urine).
Allergic contact dermatitis A hypersensitivity reaction exists after sensitization to specific substances (e.g., the 
nickel in jewelry, the rubber in gloves, or the glues in some shoes). Localization 
may suggest this diagnosis, but patch tests are needed to definitively establish 
it. This diagnosis may coexist with atopic dermatitis.
Frictional lichenoid dermatitis Shiny papules occur at elbows, knees, and backs of hands, probably related to fric-
tion. The diagnosis may be common, and may be more so in patients with atop-
ic dermatitis.
Other exogenous skin conditions
Scabies Infestation may produce nonspecific eczematous changes on the entire body. Bur-
rows and pustules on palms, soles, genitalia, and between fingers help to estab-
lish diagnosis.
Onchocerciasis The chronic phase may be accompanied by widespread itching and lichenification 
of the skin similar to those seen in cases of chronic atopic dermatitis.
Insect bites Secondary eczematous changes may develop in the area of the bites, especially on 
the limbs, and may be confused with atopic dermatitis.
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for the proportion of patients clear or almost clear
of atopic dermatitis at three weeks in five vehicle-
controlled trials involving 783 patients was 2.72
(95 percent confidence interval, 1.84 to 4.03).
 
46
 
 For
0.03 percent and 0.1 percent tacrolimus, the rate
ratios for the proportion of patients who were clear
or who had excellent improvement at 12 weeks
were 4.50 (95 percent confidence interval, 2.91 to
6.96) and 5.62 (95 percent confidence interval, 3.67
to 8.61), respectively, in three vehicle-controlled
trials involving 656 patients.
 
46
 
 Short-term studies
suggest that 0.1 percent topical tacrolimus may
be similar in strength to potent topical corticoste-
roids,
 
46
 
 whereas topical pimecrolimus is consid-
erably weaker.
 
40,47
 
 
Few long-term studies compare intermittent use
of topical calcineurin inhibitors with intermittent
use of topical corticosteroids. A 12-month vehicle-
controlled study of children with atopic dermatitis
showed that early use of pimecrolimus reduced the
frequency of flares from 51 percent to 28 percent,
 
48
 
although early use of mild topical corticosteroids
might have shown similar effects.
Topical calcineurin inhibitors do not cause skin
thinning. Both tacrolimus and pimecrolimus are
associated with mild burning sensations when ap-
plied to the skin (Table 3). Five-year studies show
a good safety profile for these agents.
 
49
 
 In the Unit-
ed Kingdom, the National Institute of Clinical Ex-
cellence approves the use of topical tacrolimus for
children older than two years of age with moderate-
to-severe atopic dermatitis not controlled by topical
corticosteroids, and of topical pimecrolimus as a
second-line option for resistant dermatitis of the
head and neck.
 
50
 
 In the United States, both of these
topical calcineurin inhibitors are approved as sec-
ond-line agents, and the site of application is not
restricted for pimecrolimus.
In March 2005, the Food and Drug Administra-
tion issued an alert to health care professionals con-
cerning a potential link between topical pimecroli-
mus and tacrolimus and cancer (mainly lymphoma
and skin cancer) on the basis of studies in animals,
case reports, and knowledge of how these drugs
work.
 
51,52
 
 The alert emphasizes the importance of
using these preparations only as labeled and when
first-line treatment has failed or cannot be tolerated.
 
Other Topical Agents
 
A study of a refined-coal cream used on one side of
the body in adults with mild-to-moderate atopic
dermatitis as compared with 1 percent hydrocorti-
sone used on the other side suggested similar effi-
cacy after four weeks.
 
53
 
 There is insufficient evi-
dence to conclude whether topical cromoglycate
preparations are effective.
 
30,54
 
 Other topical treat-
ments — such as St. John’s wort cream, vitamin B
 
12
 
,
and licorice gel — whose use is supported by sin-
gle small, randomized trials require further evalu-
ation before they can be recommended for the treat-
ment of atopic dermatitis.
 
Oral Antihistamines
 
Evidence is lacking to support the use of antihis-
tamines for the treatment of atopic dermatitis,
 
55
 
 al-
though they are sometimes recommended for their
sedative effects.
 
56
 
 Reports on nonsedative antihis-
tamines are conflicting.
 
30,56,57
 
 The largest study
failed to demonstrate any overall benefit from pro-
longed use of cetirizine in children with atopic der-
matitis.
 
58
 
Topical Doxepin
 
Topical doxepin produces some relief from itching
within 48 hours. However, a clinically useful bene-
ficial effect on disease severity has yet to be shown,
and drowsiness may be a problem.
 
30
 
Antibiotic Agents
 
Secondary infection with 
 
S. aureus
 
 is common (Fig.
3) and usually is treated with short courses of antibi-
otics such as floxacillin, cephalexin, or amoxicillin–
clavulanate. One randomized trial found no benefit
to prescribing floxacillin continually for four weeks
as compared with placebo, and methicillin-resis-
tant strains were more common in those who were
prescribed antibiotics.
 
59
 
 Although combinations of
topical corticosteroids and antibiotics are used for
atopic dermatitis, no good evidence suggests that
they offer additional benefits as compared with
topical corticosteroids alone.
 
30
 
Ultraviolet Light
 
Randomized clinical trials have shown that ultravi-
olet light (ultraviolet B, narrow-band ultraviolet B,
and high-intensity ultraviolet A) is beneficial for
atopic dermatitis in the short term.
 
30
 
 Burning and
itching may occur, and carcinogenicity is a long-
term concern. Phototherapy is usually used as a sec-
ond- or third-line treatment.
 
31
 
Immunosuppressive Agents
 
A brief course of oral corticosteroids (less than three
weeks) may be used to control a flare of severe dis-
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ease, although data from randomized clinical trials
are lacking. Ongoing use of systemic immunosup-
pressive agents (oral corticosteroids, cyclosporine,
azathioprine, mycophenolate, and interferon gam-
ma) is limited by adverse effects and is usually re-
served for people with severe disease who do not
respond to other measures.
 
30,43
 
Nonpharmacologic Approaches
 
Avoiding foods suspected to cause flares may be
helpful in young children with severe disease, but
usually is not helpful in adults.
 
30,60
 
 Little evidence
supports dietary exclusion of milk and eggs in un-
selected cases.
 
61
 
 Some evidence supports egg-free
diets in infants with atopic dermatitis who produce
IgE antibodies to egg protein.
 
60
 
 No good evidence
supports highly restrictive diets, which can some-
times cause malnutrition.
 
62
 
 Studies have failed to
show clinically useful benefits from supplements
such as evening primrose oil, borage oil,
 
63
 
 zinc, pyr-
idoxine, or vitamin E,
 
30
 
 or from viable lactobacilli
(probiotics).
 
30,64
 
Small randomized trials support psychological
approaches such as behavior therapy (to reduce the
habit of scratching) and relaxation therapy.
 
30
 
 Pa-
rental-education programs and demonstration of
topical treatments by caregivers may be helpful.
 
65,66
 
Reduction of house-dust-mite allergen can reduce
severity scores for atopic dermatitis, but the clin-
ical relevance and sustainability of such reductions
is unknown.
 
30
 
 Impermeable mattress covers are
very effective in reducing levels of mite antigens,
but they have no clear clinical benefit.
 
67
 
No good evidence supports the use of bandages
containing zinc paste. The use of “wet wraps” (an
outer dry bandage overlying an inner damp bandage
used over either emollients or topical corticoste-
roids) has become a popular second- or third-line
measure for children with resistant atopic dermati-
tis but is not supported by randomized trials, and
enhanced systemic absorption remains a con-
cern.
 
41
 
 No good data support alternative or com-
plementary therapies such as homeopathy and
bioresonance.
 
30
 
Randomized trials are lacking to assess the bene-
fits of many simple interventions, such as emol-
lients and other nonpharmacologic approaches.
 
30
 
The lack of common outcome measures hinders
meaningful comparisons across trials.
 
11
 
 Trials
with active comparators are needed to inform
choices among agents.
 
47
 
 Data on the optimal use
of topical corticosteroids are needed, along with
long-term data on adverse events. Data concerning
the long-term safety of topical tacrolimus and
pimecrolimus are also needed. The benefits of rou-
tine allergy testing require clarification. Moreover,
it is unclear whether early aggressive therapy in chil-
dren with atopic dermatitis alters the natural histo-
ry of the disease.
The American Academy of Dermatology recently
published evidence-based guidelines for atopic
dermatitis that contain recommendations that are
consistent with the evidence summarized in this
article.
 
43 
 
In addition, many useful Web sites are
available (Table 4).
Patients and families, such as the girl and her
mother who are described in the vignette, often have
concerns about topical corticosteroids that can be
alleviated by appropriate education.
 
68
 
 Patients
and families should be taught about the course of
atopic dermatitis; that is, that a single cause and
cure are unlikely, although good control is nearly
areas of uncertainty
guidelines
conclusions
and recommendations
 
Figure 3. Acute, Secondary Infection in an Infant
with Atopic Dermatitis. 
 
Widespread moist, exudative lesions and crusting are 
present.
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always possible. Discussions should be supplement-
ed by written information and a demonstration of
the use of topical treatment.
For the girl in the vignette, I would recommend
inducing a remission with once-daily application
of a potent topical corticosteroid to the limbs and
trunk for 10 days before scheduling a second visit
to evaluate progress. Although data to support the
use of emollients are limited, I would attempt to
maintain remission by liberal use of emollients only,
with recourse to five-day courses of potent or mod-
erate-strength topical corticosteroids for flares.
 
33
 
If such a regimen failed to maintain adequate qual-
ity of life, I would introduce “weekend therapy” —
that is, the application of a potent corticosteroid
to new and previously active sites of atopic derma-
titis each Saturday and Sunday evening to reduce
flares.
 
34
 
 Alternatively, intermittent use of topical tac-
rolimus or pimecrolimus may be used to reduce
flares.
 
50
 
 If facial dermatitis requires continual use
of mild topical corticosteroids, I would recommend
the use of topical tacrolimus, 0.03 percent, twice
daily for three weeks and then once daily until the
atopic dermatitis clears up.
 
50
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